BioTime, Inc. to Announce Third Quarter Results on November 3, 2016
October 24 2016 - 7:00AM
Business Wire
BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology
company with a focus on pluripotent stem cell technologies, today
announced that it will release third quarter financial and
operating results on Thursday, November 3, 2016, after the close of
the U.S. financial markets. The Company will host a conference call
and webcast on Thursday, November 3, 2016, at 4:30 p.m. Eastern
Time / 1:30 p.m. Pacific Time to discuss the results and recent
corporate developments.
The conference call dial-in number in the U.S./Canada is 1-(877)
407-0784. For international participants outside the U.S./Canada,
the dial-in number is (201) 689-8560. For all callers, please refer
to the “BioTime, Inc. Conference Call.” The live webcast can be
accessed on the “Events & Presentations” page of the “Investors
& Media” section on the company’s website at
http://www.biotimeinc.com/.
A replay of the conference call will be available for seven
business days beginning about two hours after the conclusion of the
live call, by calling toll-free from U.S./Canada: 1-844-512-2921;
international callers dial 1-412-317-6671. Use the Conference ID
13648138. Additionally, the archived webcast will be available on
the “Events & Presentations” page of the “Investors &
Media” section on the company’s website at
http://www.biotimeinc.com/.
About BioTime
BioTime, Inc. is a clinical-stage biotechnology company focused
on developing and commercializing novel therapies developed from
what the Company believes to be the world’s premier collection of
pluripotent cell assets. The foundation of BioTime’s core
therapeutic technology platform is pluripotent cells that are
capable of becoming any of the cell types in the human body.
Pluripotent cells have potential application in many areas of
medicine with large unmet patient needs, including various
age-related degenerative diseases and degenerative conditions for
which there presently are no cures. Unlike pharmaceuticals that
require a molecular target, therapeutic strategies based on the use
of pluripotent cells are generally aimed at regenerating or
replacing affected cells and tissues, and therefore may have
broader applicability than pharmaceutical products.
In addition to the development of therapeutics, BioTime’s
research and other activities have resulted, over time, in the
creation of other subsidiaries that address other non-therapeutic
market opportunities such as cancer diagnostics, drug development
and cell research products, and mobile health software
applications.
BioTime common stock is traded on the NYSE MKT and TASE under
the symbol BTX. For more information, please visit
www.biotimeinc.com or connect with the company on Twitter,
LinkedIn, Facebook, YouTube, and Google+.
To receive ongoing BioTime corporate communications, please
click on the following link to join the Company’s email alert list:
http://news.biotimeinc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161024005496/en/
Investor Contact:EVC Group, Inc.Matt Haines,
917-733-9297mhaines@evcgroup.comorMedia Contact:Gotham
Communications, LLCBill Douglass,
646-504-0890bill@gothamcomm.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Sep 2023 to Sep 2024